Serena Granziera, MD; Alexander T. Cohen, MD, MBBS, MSc
Potential Conflicts of Interest: Dr. Cohen: Support for travel to meetings for the study or other purposes and fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like: Pfizer, Bristol-Myers Squibb; Board membership: Bayer, Bristol-Myers Squibb, Daiichi, Johnson & Johnson, Pfizer, Portola, Sanofi; Consultancy, payment for lectures including service on speakers bureaus, payment for development of educational presentations, travel/accommodations/meeting expenses unrelated to activities listed: Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi, Schering-Plough, Takeda; Other: Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, U.K. Government All-Party Working Group on Thrombosis, U.K. Thromboprophylaxis Forum.
Granziera S, Cohen AT. Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. Ann Intern Med. 2013;159:502. doi: 10.7326/0003-4819-159-7-201310010-00017
Download citation file:
Published: Ann Intern Med. 2013;159(7):502.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use